Evidence map›Paper›PMID 33389014›Full record

ReviewCancer immunology, immunotherapy : CII2021

Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment.

Samuel S Widodo, Ryan A Hutchinson, Yitong Fang, Stefano Mangiola, Paul J Neeson, Phillip K Darcy, Alexander D Barrow, Christopher M Hovens, Marija Dinevska, Stanley S Stylli and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Transcriptional signature of CD56Frontiers in immunology · 2024
    Article
  7. High-Throughput Multiplex Immunohistochemistry of Glioma Organoids.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samuel S Widodo *Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia.
Ryan A Hutchinson *Department of Clinical Pathology, The University of Melbourne, Melbourne, Australia.
Yitong FangDepartment of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia.
Stefano MangiolaBioinformatics Division, The Walter and Eliza Hall Institute, Parkville, Australia.
Paul J NeesonCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
Phillip K DarcyCancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
Alexander D BarrowDepartment of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia.
Christopher M HovensDepartment of Surgery, The University of Melbourne, Parkville, Australia.
Marija DinevskaDepartment of Surgery, The University of Melbourne, Parkville, Australia.
Stanley S StylliDepartment of Surgery, The University of Melbourne, Parkville, Australia.
Theo MantamadiotisDepartment of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia. theom@unimelb.edu.au.ORCID http://orcid.org/0000-0003-3971-5380

Funding

Cass Foundation 28534
6 · The paper itself

Abstract

Recent developments in cancer immunotherapy promise better outcomes for cancer patients, although clinical trials for difficult to treat cancers such as malignant brain cancer present special challenges, showing little response to first generation immunotherapies. Reasons for differences in immunotherapy response in some cancer types are likely due to the nature of tumor microenvironment, which harbors multiple cell types which interact with tumor cells to establish immunosuppression. The cell types which appear to hold the key in regulating tumor immunosuppression are the tumor-infiltrating immune cells. The current standard treatment for difficult to treat cancer, including the most malignant brain cancer, glioblastoma, continues to offer a bleak outlook for patients. Immune-profiling and correlation with pathological and clinical data will lead to a deeper understanding of the tumor immune microenvironment and contribute toward the selection, optimization and development of novel precision immunotherapies. Here, we review the current understanding of the tumor microenvironmental landscape in glioblastoma with a focus on next-generation technologies including multiplex immunofluorescence and computational approaches to map the brain tumor microenvironment to decipher the role of the immune system in this lethal malignancy.

Indexed as

Computer SimulationAnimalsAntineoplastic AgentsBiomarkers, TumorBrain NeoplasmsHumansImmune ToleranceImmunohistochemistryImmunotherapyMolecular Targeted TherapyPrecision MedicineTumor MicroenvironmentAntineoplastic AgentsBiomarkers, TumorComputational deconvolutionGlioblastomaGliomaImmune cellsMultiplex immunohistochemistryTumor microenvironment

Identifiers

PMID33389014
PMCPMC10991574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.